Vapotherm Inc.

119 articles about Vapotherm Inc.

• Vapotherm Announces Debt Amendment and NYSE Continued Listing Standard Notice

  10/3/2022

  Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, announced that, on September 30, 2022, the Company entered into an Amendment No. 2 to Loan and Security Agreement with SLR Investment Corp., as Collateral Agent, and the lenders party thereto.

• Vapotherm to Participate in the Canaccord Genuity 42nd Annual Growth Conference

  8/4/2022

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity 42nd Annual Growth Conference.

• Vapotherm Reports Second Quarter 2022 Financial Results

  8/3/2022

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced second quarter 2022 financial results.

• Vapotherm to Report Second Quarter 2022 Financial Results

  7/20/2022

  Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, announced that it will release financial results for the second quarter of 2022 after the close of trading on Wednesday, August 3, 2022.

• Vapotherm Reports First Quarter 2022 Financial Results

  5/4/2022

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced first quarter 2022 financial results.

• Vapotherm Announces Preliminary Revenue for First Quarter of 2022 and Withdraws 2022 Annual Guidance

  4/6/2022

  Vapotherm, Inc., announced preliminary unaudited revenue for the quarter ended March 31, 2022. The Company also announced withdrawal of its full year 2022 revenue guidance together with its full year 2022 gross margin, operating expense and adjusted EBITDA guidance.

• Vapotherm Launches Strategic Partnership with Carnegie Mellon University to Deliver a Tailored Artificial Intelligence (AI) Program to Drive Better Outcomes for Patients Suffering from Chronic Respiratory Diseases

  3/3/2022

  Vapotherm, Inc. announced a strategic partnership with Carnegie Mellon University, a world class AI research institution, to deliver a tailored artificial intelligence program for Vapotherm employees.

• Vapotherm Reports Fourth Quarter and Fiscal Year 2021 Financial Results

  2/24/2022

  Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders announced fourth quarter and fiscal year 2021 financial results.

• Vapotherm to Report Fourth Quarter and Full Year 2021 Financial Results

  2/10/2022

  Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), today announced that it will release financial results for the fourth quarter and full year 2021 after the close of trading on Thursday, February 24, 2022.

• Vapotherm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/22/2021

  Vapotherm, Inc. today announced the company will be participating in a fireside chat at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.

• Vapotherm Reports Third Quarter 2021 Financial Results

  11/3/2021

  Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company, today announced third quarter 2021 financial results.

• Vapotherm to Report Third Quarter 2021 Financial Results

  10/20/2021

  Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the third quarter of 2021 after the close of trading on Wednesday, November 3, 2021.

• Vapotherm Increases Fiscal Year 2021 Revenue Outlook and Announces Expansion of Production Capacity

  9/8/2021

  Vapotherm, Inc., updated its fiscal year 2021 revenue expectations and announced it will expand its disposables production capacity.

• Vapotherm Announces FDA 510(k) Clearance for HVT 2.0 Next Generation Platform

  8/30/2021

  Vapotherm, Inc., announced it has received 510 clearance from the US Food and Drug Administration for HVT 2.0.

• Vapotherm Reports Second Quarter 2021 Financial Results

  8/9/2021

  Vapotherm, Inc. today announced second quarter 2021 financial results.

• Vapotherm to Participate in the Canaccord Genuity 41st Annual Growth Conference

  7/28/2021

  Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, announced that its management team will be participating in the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 via webcast.

• Vapotherm to Report Second Quarter 2021 Financial Results

  7/21/2021

  Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the second quarter of 2021 after the close of trading on Monday, August 9, 2021.

• Vapotherm to Host First Investor Day

  6/9/2021

  Vapotherm, Inc. today announced that its management team will be hosting their first investor day on Wednesday, June 23, 2021 beginning at 10:00AM ET.

• Vapotherm to Participate in the William Blair 41st Annual Growth Stock Conference

  5/25/2021

  Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, announced that its management team will be participating in the William Blair 41st Annual Growth Stock Conference on Tuesday, June 1, 2021 via webcast.

•  Vapotherm to Participate in the Bank of America Securities 2021 Health Care Conference

  5/6/2021

  Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, announced that its management team will be participating in the Bank of America Securities 2021 Health Care Conference on Wednesday, May 12, 2021 via webcast.